Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

Core Viewpoint - Novo Nordisk's and Eli Lilly's weight-loss drugs are recommended as the primary treatment options for obesity and its related complications by a major European medical association [1] Company Summary - Novo Nordisk and Eli Lilly are positioned as leaders in the obesity treatment market with their respective blockbuster weight-loss medications [1] - The endorsement from a prominent medical association may enhance the market adoption of these drugs, potentially leading to increased sales and market share for both companies [1] Industry Summary - The recommendation highlights a growing recognition of obesity as a significant health issue, prompting a shift in treatment protocols towards pharmaceutical interventions [1] - The endorsement may influence healthcare providers' prescribing habits, thereby impacting the overall landscape of obesity treatment options available in Europe [1]